PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för isorhapontigenin. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

26 hits

Bibliografisk träff 2024-09-25

Investigation of the molecular mechanisms underlying the anti-inflammatory and antitumour effects of isorhapontigenin: Insights from in vitro and in vivo studies.

Kowalczyk T, Piekarski J, Merecz-Sadowska A, Muskała M, Sitarek P.

Biomed Pharmacother · review; journal article · DOI 10.1016/j.biopha.2024.117479

Bibliografisk träff 2024-07-26

Isorhapontigenin delays senescence and matrix degradation of nucleus pulposus cells via PI3K/AKT/mTOR-mediated autophagy pathway in vitro and alleviates intervertebral disc degeneration in vivo.

Wang Z, Ma J, Sun Y, Jin Z, Zheng R, Li Y, Yu H, Ye H, Wu Y, Ge X, Chen Z.

Int Immunopharmacol · journal article · DOI 10.1016/j.intimp.2024.112717

Bibliografisk träff 2024-07-24

Elucidating the potential of isorhapontigenin in targeting the MgrA regulatory network: a paradigm shift for attenuating MRSA virulence.

Liu L, Wang L, Liu X, Wang B, Guo X, Wang Y, Xu Y, Guan J, Zhao Y.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.00611-24

Bibliografisk träff 2024-06-15

Isorhapontigenin inhibition of basal muscle-invasive bladder cancer attributed to its downregulation of SNHG1 and DNMT3b.

Meng H, Yang R, Lin Q, Du W, Chu Z, Cao Y, Du M, Zhao Y, Xu J, Yang Z, Xie X, He L, Huang C.

BMC Cancer · research-article; journal article · DOI 10.1186/s12885-024-12490-5

Bibliografisk träff 2024-06-05

Exploring the potential of isorhapontigenin: attenuating Staphylococcus aureus virulence through MgrA-mediated regulation.

Yuan L, Xi H, Luo Z, Liu M-f, Chen Q, Zhu Q, Zhao R, Sheng Y-y.

mSphere · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/msphere.00317-24

Bibliografisk träff 2024-05-10

Inhibitory nitric oxide production and cytotoxic activities of phenolic compounds from Gnetum montanum Markgr.

Ngo Van H, Van CP, Thi TV, Viet DN, Huu TB, Tien DN, Quang MB, Le Tuan A, Thi TP, Nguyen Van D, Vu Xuan H, Hoang Le Tuan A.

Nat Prod Res · journal article · DOI 10.1080/14786419.2024.2345750

Bibliografisk träff 2024-02-01

Transcriptome Analysis Reveals Anti-Cancer Effects of Isorhapontigenin (ISO) on Highly Invasive Human T24 Bladder Cancer Cells.

Li AH, Park SY, Li P, Zhou C, Kluz T, Li J, Costa M, Sun H.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms25031783

Bibliografisk träff 2023-11-10

Antiproliferative Effects in Colorectal Cancer and Stabilisation in Cyclodextrins of the Phytoalexin Isorhapontigenin.

Navarro-Orcajada S, Vidal-Sánchez FJ, Conesa I, Escribano-Naharro F, Matencio A, López-Nicolás JM.

Biomedicines · research-article; journal article · DOI 10.3390/biomedicines11113023

Bibliografisk träff 2023-08-25

Inhibition of TLR4 Signaling by Isorhapontigenin Targeting of the AHR Alleviates Cerebral Ischemia/Reperfusion Injury.

Liu J, Mu D, Xu J, Liu Y, Zhang G, Tang Y, Wang D, Wang F, Liang D, Hou Y, Hou Y.

J Agric Food Chem · journal article · DOI 10.1021/acs.jafc.3c00152

Bibliografisk träff 2023-08-22

Isorhapontigenin (ISO) inhibits malignant cell transformation, migration, and invasion through MEG3/NEDD9 signaling in Cr(VI)-transformed cells.

Shi S, Li J, Zhang Z, Tu H, Max C.

Toxicol Appl Pharmacol · research-article; journal article · DOI 10.1016/j.taap.2023.116661

Bibliografisk träff 2023-03-01

Isorhapontigenin Attenuates Cardiac Microvascular Injury in Diabetes via the Inhibition of Mitochondria-Associated Ferroptosis Through PRDX2-MFN2-ACSL4 Pathways.

Chen Y, Li S, Yin M, Li Y, Chen C, Zhang J, Sun K, Kong X, Chen Z, Qian J.

Diabetes · research support, non-u.s. gov't; journal article · DOI 10.2337/db22-0553

Bibliografisk träff 2022-10-01

[Effects of Isorhapontigenin on Lipopolysaccharide-Induced Acute Lung Injury in Mice].

Yao P, Deng R, Li Z, Zhang Z.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao · journal article; english abstract · DOI 10.3881/j.issn.1000-503x.14799

Bibliografisk träff 2022-08-31

Induction of RAC1 protein translation and MKK7/JNK-dependent autophagy through dicer/miR-145/SOX2/miR-365a axis contributes to isorhapontigenin (ISO) inhibition of human bladder cancer invasion.

Hua X, Xiang D, Guo M, Qian X, Chen R, Li T, Tian Z, Xu J, Huang C, Xie Q, Huang C.

Cell Death Dis · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41419-022-05205-w

Bibliografisk träff 2022-08-12

Isorhapontigenin ameliorates high glucose-induced podocyte and vascular endothelial cell injuries via mitigating oxidative stress and autophagy through the AMPK/Nrf2 pathway.

Tian H, Zheng X, Wang H.

Int Urol Nephrol · journal article · DOI 10.1007/s11255-022-03325-y

Bibliografisk träff 2022-08-12

Exploring flexibility, intermolecular interactions and ADMET profiles of anti-influenza agent isorhapontigenin: A quantum chemical and molecular docking study.

Bangaru S, Madhu G, Srinivasan M, Manivannan P.

Heliyon · research-article; journal article · DOI 10.1016/j.heliyon.2022.e10122

Bibliografisk träff 2022-06-09

Isorhapontigenin Modulates SOX9/TOLLIP Expression to Attenuate Cell Apoptosis and Oxidative Stress in Paraquat-Induced Acute Kidney Injury.

Zheng Q, Zhang Y, Wang X, Wang F, Zhao H.

Oxid Med Cell Longev · research-article; journal article · DOI 10.1155/2022/3328623

Bibliografisk träff 2022-05-15

Induction of p27 contributes to inhibitory effect of isorhapontigenin (ISO) on malignant transformation of human urothelial cells.

Huang M, Hua X, Xu J, Tian Z, Wang J, Chen H, Wang X, Shu P, Ye H, Shu J, Huang C.

Cell Cycle · research-article; journal article · DOI 10.1080/15384101.2022.2074623

Bibliografisk träff 2022-01-01

Isorhapontigenin prevents β‑amyloid‑associated cognitive impairments through activation of the PI3K/AKT/GSK‑3β pathway.

Ma Q, Li C, He Y, Liu P, Gong F, Zhang W.

Acta Neurobiol Exp (Wars) · journal article · DOI 10.55782/ane-2022-037

Bibliografisk träff 2021-07-28

Isorhapontigenin (ISO) inhibits EMT through FOXO3A/METTL14/VIMENTIN pathway in bladder cancer cells.

Zhang N, Hua X, Tu H, Li J, Zhang Z, Max C.

Cancer Lett · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.canlet.2021.07.041

Bibliografisk träff 2021-06-08

Isorhapontigenin ameliorates cerebral ischemia/reperfusion injury via modulating Kinase Cε/Nrf2/HO-1 signaling pathway.

Xue Z, Zhao K, Sun Z, Wu C, Yu B, Kong D, Xu B.

Brain Behav · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/brb3.2143

Bibliografisk träff 2021-03-30

Isorhapontigenin alleviates lipopolysaccharide-induced acute lung injury via modulating Nrf2 signaling.

Yao P, Zhang Z, Cao J.

Respir Physiol Neurobiol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.resp.2021.103667

Bibliografisk träff 2020-11-01

Isorhapontigenin protects against doxorubicin-induced cardiotoxicity via increasing YAP1 expression.

Wang P, Wang M, Hu Y, Chen J, Cao Y, Liu C, Wu Z, Shen J, Lu J, Liu P.

Acta Pharm Sin B · research-article; journal article · DOI 10.1016/j.apsb.2020.10.017

Bibliografisk träff 2020-03-23

Isorhapontigenin Improves Diabetes in Mice via Regulating the Activity and Stability of PPARγ in Adipocytes.

Chu XY, Yang SZ, Zhu MQ, Zhang DY, Shi XC, Xia B, Yuan Y, Liu M, Wu JW.

J Agric Food Chem · journal article · DOI 10.1021/acs.jafc.0c00515

Bibliografisk träff 2019-12-01

Isorhapontigenin Suppresses Interleukin-1β-Induced Inflammation and Cartilage Matrix Damage in Rat Chondrocytes.

Ma Y, Tu C, Liu W, Xiao Y, Wu H.

Inflammation · journal article · DOI 10.1007/s10753-019-01092-0

Bibliografisk träff 2019-08-25

Isorhapontigenin, a resveratrol analogue selectively inhibits ADP-stimulated platelet activation.

Ravishankar D, Albadawi DAI, Chaggar V, Patra PH, Williams HF, Salamah M, Vaiyapuri R, Dash PR, Patel K, Watson KA, Vaiyapuri S.

Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2019.172627

Bibliografisk träff 2001-07-01

A novel cyclooxygenase-inhibitory stilbenolignan from the seeds of Aiphanes aculeata.

Lee D, Cuendet M, Vigo JS, Graham JG, Cabieses F, Fong HH, Pezzuto JM, Kinghorn AD.

Org Lett · research support, u.s. gov't, p.h.s.; journal article · DOI 10.1021/ol015985j

Go to research.

Publications in the selection

Investigation of the molecular mechanisms underlying the anti-inflammatory and antitumour effects of isorhapontigenin: Insights from in vitro and in vivo studies.

Isorhapontigenin delays senescence and matrix degradation of nucleus pulposus cells via PI3K/AKT/mTOR-mediated autophagy pathway in vitro and alleviates intervertebral disc degeneration in vivo.

Elucidating the potential of isorhapontigenin in targeting the MgrA regulatory network: a paradigm shift for attenuating MRSA virulence.

Isorhapontigenin inhibition of basal muscle-invasive bladder cancer attributed to its downregulation of SNHG1 and DNMT3b.

Exploring the potential of isorhapontigenin: attenuating <i>Staphylococcus aureus</i> virulence through MgrA-mediated regulation.

Inhibitory nitric oxide production and cytotoxic activities of phenolic compounds from <i>Gnetum montanum</i> Markgr.

Transcriptome Analysis Reveals Anti-Cancer Effects of Isorhapontigenin (ISO) on Highly Invasive Human T24 Bladder Cancer Cells.

Antiproliferative Effects in Colorectal Cancer and Stabilisation in Cyclodextrins of the Phytoalexin Isorhapontigenin.

Inhibition of TLR4 Signaling by Isorhapontigenin Targeting of the AHR Alleviates Cerebral Ischemia/Reperfusion Injury.

Isorhapontigenin (ISO) inhibits malignant cell transformation, migration, and invasion through MEG3/NEDD9 signaling in Cr(VI)-transformed cells.

Isorhapontigenin Attenuates Cardiac Microvascular Injury in Diabetes via the Inhibition of Mitochondria-Associated Ferroptosis Through PRDX2-MFN2-ACSL4 Pathways.

[Effects of Isorhapontigenin on Lipopolysaccharide-Induced Acute Lung Injury in Mice].

Induction of RAC1 protein translation and MKK7/JNK-dependent autophagy through dicer/miR-145/SOX2/miR-365a axis contributes to isorhapontigenin (ISO) inhibition of human bladder cancer invasion.

Isorhapontigenin ameliorates high glucose-induced podocyte and vascular endothelial cell injuries via mitigating oxidative stress and autophagy through the AMPK/Nrf2 pathway.

Exploring flexibility, intermolecular interactions and ADMET profiles of anti-influenza agent isorhapontigenin: A quantum chemical and molecular docking study.

Isorhapontigenin Modulates SOX9/TOLLIP Expression to Attenuate Cell Apoptosis and Oxidative Stress in Paraquat-Induced Acute Kidney Injury.

Induction of p27 contributes to inhibitory effect of isorhapontigenin (ISO) on malignant transformation of human urothelial cells.

Isorhapontigenin prevents β‑amyloid‑associated cognitive impairments through activation of the PI3K/AKT/GSK‑3β pathway.

Isorhapontigenin (ISO) inhibits EMT through FOXO3A/METTL14/VIMENTIN pathway in bladder cancer cells.

Isorhapontigenin ameliorates cerebral ischemia/reperfusion injury via modulating Kinase Cε/Nrf2/HO-1 signaling pathway.

Isorhapontigenin alleviates lipopolysaccharide-induced acute lung injury via modulating Nrf2 signaling.

Isorhapontigenin protects against doxorubicin-induced cardiotoxicity <i>via</i> increasing YAP1 expression.

Isorhapontigenin Improves Diabetes in Mice via Regulating the Activity and Stability of PPARγ in Adipocytes.

Isorhapontigenin Suppresses Interleukin-1β-Induced Inflammation and Cartilage Matrix Damage in Rat Chondrocytes.

Isorhapontigenin, a resveratrol analogue selectively inhibits ADP-stimulated platelet activation.

A novel cyclooxygenase-inhibitory stilbenolignan from the seeds of Aiphanes aculeata.